Cationic lipids and methods for the delivery of therapeutic agents
View Patent ↗The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid in vivo. The compositions of the present invention are highly potent, thereby allowing effective know-down of a specific target protein at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art.
1. A cationic lipid of Formula VIII having the following structure:
or salts thereof, wherein:
R 1 and R 2 are either the same or different and are independently an optionally substituted C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl, or R 1 and R 2 may join to form an optionally substituted heterocyclic ring of 4 to 6 carbon atoms and 1 or 2 heteroatoms selected from the group consisting of nitrogen (N), oxygen (O), and mixtures thereof;
R 3 is either absent or is hydrogen (H) or a C 1 -C 6 alkyl to provide a quaternary amine;
R 4 , R 5 , and R 6 are either the same or different and are independently an optionally substituted C 12 -C 24 alkyl, C 12 -C 24 alkenyl, C 12 -C 24 alkynyl, or C 12 -C 24 acyl; and
n is 0, 1, 2, 3, or 4.
2. The cationic lipid of claim 1 , wherein R 4 , R 5 , and R 6 are independently selected from the group consisting of a dodecadienyl moiety, a tetradecadienyl moiety, a hexadecadienyl moiety, an octadecadienyl moiety, an icosadienyl moiety, a dodecatrienyl moiety, a tetradectrienyl moiety, a hexadecatrienyl moiety, an octadecatrienyl moiety, an icosatrienyl moiety, and a phytanyl moiety.
3. The cationic lipid of claim 2 , wherein the octadecadienyl moiety is a linoleyl moiety.
4. The cationic lipid of claim 3 , wherein R 4 , R 5 , and R 6 are linoleyl moieties.
5. The cationic lipid of claim 2 , wherein the octadecatrienyl moiety is a linolenyl moiety or a γ-linolenyl moiety.
6. The cationic lipid of claim 1 , wherein R 1 and R 2 are both methyl groups.
7. The cationic lipid of claim 1 , having a structure selected from the group consisting of:
8. A lipid particle comprising a cationic lipid of claim 1 .
9. The lipid particle of claim 8 , wherein the particle further comprises a non-cationic lipid.
10. The lipid particle of claim 9 , wherein the non-cationic lipid is selected from the group consisting of a phospholipid, cholesterol, or a mixture of a phospholipid and cholesterol.
11. The lipid particle of claim 10 , wherein the phospholipid comprises dipalmitoylphosphatidylcholine (DPPC), distearoylphosphatidylcholine (DSPC), or a mixture thereof.
12. The lipid particle of claim 10 , wherein the cholesterol is a cholesterol derivative.
13. The lipid particle of claim 8 , wherein the particle further comprises a conjugated lipid that inhibits aggregation of particles.
14. The lipid particle of claim 13 , wherein the conjugated lipid that inhibits aggregation of particles comprises a polyethyleneglycol (PEG)-lipid conjugate.
15. The lipid particle of claim 14 , wherein the PEG-lipid conjugate comprises a PEG-diacylglycerol (PEG-DAG) conjugate, a PEG-dialkyloxypropyl (PEG-DAA) conjugate, or a mixture thereof.
16. The lipid particle of claim 8 , wherein the particle further comprises a therapeutic agent.
17. The lipid particle of claim 16 , wherein the therapeutic agent is a nucleic acid.
18. The lipid particle of claim 17 , wherein the nucleic acid is an interfering RNA.
19. The lipid particle of claim 18 , wherein the interfering RNA is selected from the group consisting of a small interfering RNA (siRNA), an asymmetrical interfering RNA (aiRNA), a microRNA (miRNA), a Dicer-substrate dsRNA, a small hairpin RNA (shRNA), and mixtures thereof.
20. The lipid particle of claim 18 , wherein the interfering RNA is an siRNA.
21. The lipid particle of claim 16 , wherein the therapeutic agent is not substantially degraded after incubation of the particle in serum at 37° C. for 30 minutes.
22. The lipid particle of claim 16 , wherein the therapeutic agent is fully encapsulated in the particle.
23. The lipid particle of claim 17 , wherein the particle has a lipid:nucleic acid mass ratio of from about 5:1 to about 15:1.
24. The lipid particle of claim 8 , wherein the particle has a median diameter of from about 30 nm to about 150 nm.
25. A pharmaceutical composition comprising a lipid particle of claim 8 and a pharmaceutically acceptable carrier.
26. A method for introducing a therapeutic agent into a cell, the method comprising:
contacting the cell with a lipid particle of claim 16 .
27. The method of claim 26 , wherein the cell is in a mammal.
28. A method for the in vivo delivery of a therapeutic agent, the method comprising:
administering to a mammal a lipid particle of claim 16 .
29. The method of claim 28 , wherein the administration is selected from the group consisting of oral, intranasal, intravenous, intraperitoneal, intramuscular, intraarticular, intralesional, intratracheal, subcutaneous, and intradermal.
30. The method of claim 28 , wherein the mammal is a human.
31. A method for treating a disease or disorder in a mammal in need thereof, the method comprising:
administering to the mammal a therapeutically effective amount of a lipid particle of claim 16 .
32. The method of claim 31 , wherein the disease or disorder is selected from the group consisting of a viral infection, a liver disease or disorder, and cancer.
33. The method of claim 31 , wherein the mammal is a human.